company background image
ITCI

Intra-Cellular TherapiesNasdaqGS:ITCI Stock Report

Last Price

US$42.66

Market Cap

US$3.9b

7D

-1.0%

1Y

28.0%

Updated

23 Jan, 2022

Data

Company Financials +
ITCI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ITCI Stock Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States.

Intra-Cellular Therapies Competitors

Pfizer

NYSE:PFE

US$296.3b

Eli Lilly

NYSE:LLY

US$220.4b

Teva Pharmaceutical Industries

NYSE:TEVA

US$9.4b

AstraZeneca

LSE:AZN

UK£135.6b

Price History & Performance

Summary of all time highs, changes and price drops for Intra-Cellular Therapies
Historical stock prices
Current Share PriceUS$42.66
52 Week HighUS$55.20
52 Week LowUS$28.40
Beta1.14
1 Month Change-17.41%
3 Month Change-0.93%
1 Year Change28.03%
3 Year Change243.76%
5 Year Change214.37%
Change since IPO326.60%

Recent News & Updates

Dec 24
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Dec 21

Intra-Cellular's Second FDA Win Makes It A Great Long-Term Investment

Intra-Cellular Therapies received FDA approval of CAPLYTA for the treatment of adults with bipolar depression. Total revenues of CAPLYTA in Q3 2021 for treatment of adults with Schizophrenia surged by 200% to $22.1 million compared to the same time period in the prior year. Two late-stage studies, Study '501 and Study '502, are using CAPLYTA as an adjunctive treatment for patients with major depressive disorder. Both studies are estimated to be completed end-2023. Intra-Cellular Therapies had $478.7 million in cash as of September 30, 2021; enough cash to fund operations for at least next 12 months of SEC Filing date November 9, 2021.

Shareholder Returns

ITCIUS PharmaceuticalsUS Market
7D-1.0%-2.5%-6.1%
1Y28.0%5.3%4.2%

Return vs Industry: ITCI exceeded the US Pharmaceuticals industry which returned 5.3% over the past year.

Return vs Market: ITCI exceeded the US Market which returned 4.2% over the past year.

Price Volatility

Is ITCI's price volatile compared to industry and market?
ITCI volatility
ITCI Average Weekly Movement9.9%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: ITCI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ITCI's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a383Sharon Mateshttps://www.intracellulartherapies.com

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders.

Intra-Cellular Therapies Fundamentals Summary

How do Intra-Cellular Therapies's earnings and revenue compare to its market cap?
ITCI fundamental statistics
Market CapUS$3.94b
Earnings (TTM)-US$259.09m
Revenue (TTM)US$70.59m

55.8x

P/S Ratio

-15.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ITCI income statement (TTM)
RevenueUS$70.59m
Cost of RevenueUS$80.32m
Gross Profit-US$9.74m
ExpensesUS$249.35m
Earnings-US$259.09m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.81
Gross Margin-13.79%
Net Profit Margin-367.06%
Debt/Equity Ratio0%

How did ITCI perform over the long term?

See historical performance and comparison

Valuation

Is Intra-Cellular Therapies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ITCI ($42.66) is trading below our estimate of fair value ($422.07)

Significantly Below Fair Value: ITCI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ITCI is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: ITCI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ITCI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ITCI is overvalued based on its PB Ratio (8.1x) compared to the US Pharmaceuticals industry average (2.1x).


Future Growth

How is Intra-Cellular Therapies forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

56.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ITCI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: ITCI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ITCI's is expected to become profitable in the next 3 years.

Revenue vs Market: ITCI's revenue (42.5% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: ITCI's revenue (42.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ITCI is forecast to be unprofitable in 3 years.


Past Performance

How has Intra-Cellular Therapies performed over the past 5 years?

-18.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ITCI is currently unprofitable.

Growing Profit Margin: ITCI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ITCI is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.

Accelerating Growth: Unable to compare ITCI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ITCI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: ITCI has a negative Return on Equity (-53.23%), as it is currently unprofitable.


Financial Health

How is Intra-Cellular Therapies's financial position?


Financial Position Analysis

Short Term Liabilities: ITCI's short term assets ($533.2M) exceed its short term liabilities ($49.9M).

Long Term Liabilities: ITCI's short term assets ($533.2M) exceed its long term liabilities ($20.3M).


Debt to Equity History and Analysis

Debt Level: ITCI is debt free.

Reducing Debt: ITCI has no debt compared to 5 years ago when its debt to equity ratio was 31%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ITCI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ITCI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Intra-Cellular Therapies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ITCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ITCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ITCI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ITCI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ITCI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Sharon Mates (68 yo)

19.67yrs

Tenure

US$5,475,679

Compensation

Dr. Sharon Mates, Ph D., co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and has been its Chairman, President and Chief Executive Officer since June 2002. Earlier in her career, Dr. Mates...


CEO Compensation Analysis

Compensation vs Market: Sharon's total compensation ($USD5.48M) is about average for companies of similar size in the US market ($USD5.28M).

Compensation vs Earnings: Sharon's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ITCI's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: ITCI's board of directors are considered experienced (8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.2%.


Top Shareholders

Company Information

Intra-Cellular Therapies, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Intra-Cellular Therapies, Inc.
  • Ticker: ITCI
  • Exchange: NasdaqGS
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$3.939b
  • Shares outstanding: 92.33m
  • Website: https://www.intracellulartherapies.com

Number of Employees


Location

  • Intra-Cellular Therapies, Inc.
  • 430 East 29th Street
  • Suite 900
  • New York
  • New York
  • 10016
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 23:14
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.